[go: up one dir, main page]

MX2017005134A - Tratamiento del cáncer con inmunoestimuladores. - Google Patents

Tratamiento del cáncer con inmunoestimuladores.

Info

Publication number
MX2017005134A
MX2017005134A MX2017005134A MX2017005134A MX2017005134A MX 2017005134 A MX2017005134 A MX 2017005134A MX 2017005134 A MX2017005134 A MX 2017005134A MX 2017005134 A MX2017005134 A MX 2017005134A MX 2017005134 A MX2017005134 A MX 2017005134A
Authority
MX
Mexico
Prior art keywords
cancer
treatment
immune stimulators
immunostimulator
subject
Prior art date
Application number
MX2017005134A
Other languages
English (en)
Other versions
MX386613B (es
Inventor
Tuthill Cynthia
S King Robert
Blobel Friedhelm
Original Assignee
Sciclone Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sciclone Pharmaceuticals Inc filed Critical Sciclone Pharmaceuticals Inc
Publication of MX2017005134A publication Critical patent/MX2017005134A/es
Publication of MX386613B publication Critical patent/MX386613B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2046—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Inorganic Chemistry (AREA)

Abstract

La presente invención proporciona composiciones y métodos para tratar un cáncer o una metástasis de este en un sujeto; en algunas modalidades, los métodos implican administrar una composición que comprende una cantidad terapéuticamente eficaz de al menos un inmunoestimulador al sujeto; en algunas modalidades, se usa una combinación de al menos dos inmunoestimuladores para el tratamiento; en algunas modalidades, la combinación incluye un péptido de timosina alfa y un inmunoestimulador adicional, y/u opcionalmente uno o más agentes anticancerosos adicionales.
MX2017005134A 2014-10-21 2015-10-21 El uso de un péptido timosina alfa y un inhibidor de pd-1 para el tratamiento de cáncer o una metástasis de este en un sujeto. MX386613B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462066862P 2014-10-21 2014-10-21
US201562215433P 2015-09-08 2015-09-08
PCT/US2015/056609 WO2016064969A1 (en) 2014-10-21 2015-10-21 Treatment of cancer with immune stimulators

Publications (2)

Publication Number Publication Date
MX2017005134A true MX2017005134A (es) 2018-02-12
MX386613B MX386613B (es) 2025-03-19

Family

ID=55748164

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017005134A MX386613B (es) 2014-10-21 2015-10-21 El uso de un péptido timosina alfa y un inhibidor de pd-1 para el tratamiento de cáncer o una metástasis de este en un sujeto.

Country Status (16)

Country Link
US (4) US9724395B2 (es)
EP (2) EP3943101A1 (es)
JP (2) JP6821560B2 (es)
KR (1) KR102589557B1 (es)
CN (2) CN113855806A (es)
AU (1) AU2015335979B2 (es)
BR (1) BR112017007817A2 (es)
CA (1) CA2962451C (es)
ES (1) ES2882080T3 (es)
IL (1) IL251761B (es)
MX (1) MX386613B (es)
RU (2) RU2020142556A (es)
SG (1) SG11201702558VA (es)
TW (2) TWI749433B (es)
WO (1) WO2016064969A1 (es)
ZA (1) ZA201702111B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016064969A1 (en) 2014-10-21 2016-04-28 Sciclone Pharmaceuticals, Inc. Treatment of cancer with immune stimulators
IL258701B2 (en) * 2015-10-21 2024-07-01 Teclison Ltd Preparations and methods for curing cancer with immune support
WO2018138682A1 (en) * 2017-01-26 2018-08-02 Immune Therapeutics Methods and compositions useful for treating cancer
CN109793891A (zh) * 2017-11-17 2019-05-24 韩震 多肽化合物在制备提高治疗性抗体疗效的佐剂中的应用与组合物及其制备方法
US12178786B2 (en) 2018-02-02 2024-12-31 Crage Medical Co., Limited Combination of cellular immunotherapy
WO2020130300A1 (ko) 2018-12-21 2020-06-25 한미약품 주식회사 신규 면역 억제 인터루킨 2
CA3161364A1 (en) * 2019-12-24 2021-07-01 Carl WALKEY Combination therapy using an il-2 receptor agonist and an immune checkpoint inhibitor
KR102545250B1 (ko) 2020-03-31 2023-06-21 한미약품 주식회사 신규한 면역 활성 인터루킨 2 아날로그
CN112023027B (zh) * 2020-07-21 2023-03-14 广东海洋大学 胸腺素或其衍生物的应用和治疗快感缺乏型抑郁症的药物
CN111821424B (zh) * 2020-07-21 2023-03-31 广东海洋大学深圳研究院 胸腺素及其衍生物的应用和治疗抑郁症的药物
IL304365B2 (en) 2021-03-31 2025-04-01 Hanmi Pharmaceutical Co Ltd A novel conjugate of an IL2 immunostimulatory analog and method of preparation thereof
CA3235940A1 (en) * 2021-10-21 2023-04-27 Jeffrey A. BACHA Compositions and methods for treatment of hyperproliferative, inflammatory, and immunological diseases, and infections
KR20240102886A (ko) 2022-12-23 2024-07-03 한미약품 주식회사 면역 활성 인터루킨 2 아날로그 결합체를 포함하는 제제

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
DE2604845A1 (de) 1976-02-07 1977-08-18 Knoll Ag Neue piperazinderivate
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
AR036993A1 (es) 2001-04-02 2004-10-20 Wyeth Corp Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
UA80957C2 (en) * 2001-11-01 2007-11-26 Sciclone Pharmaceuticals Inc Method of administering a thymosin alpha 1 peptide
CN101072582B (zh) * 2004-12-06 2012-06-27 赛生制药有限公司 作为癌症疫苗佐剂的α胸腺肽
EP2418278A3 (en) * 2005-05-09 2012-07-04 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
EP1948214A4 (en) 2005-11-08 2009-12-30 Medarex Inc ANTI-TNF-ALPHA TREATMENT FOR TREATING ENTEROCOLITIS ASSOCIATED WITH IMMUNOSTIMULATORY THERAPEUTIC ANTIBODY TREATMENT
JP5372751B2 (ja) 2006-07-21 2013-12-18 ギリアード サイエンシーズ， インコーポレイテッド Ａｚａ−ペプチドプロテアーゼ阻害剤
US20080300166A1 (en) * 2007-06-01 2008-12-04 Sciclone Pharmaceuticals, Inc. Treatment of Melanoma with Alpha Thymosin Peptides
KR20100040896A (ko) 2007-07-06 2010-04-21 길리애드 사이언시즈, 인코포레이티드 치료제의 약동학적 특성의 조절제
US20090021740A1 (en) * 2007-07-17 2009-01-22 Chung Yuan Christian University Optical sensor and method for measuring blood gas
AU2008335840A1 (en) 2007-12-12 2009-06-18 Sciclone Pharmaceuticals, Inc. Treatment of melanoma with alpha thymosin peptides in combination with antibodies against cytotoxic T lymphocyte-associated antigen 4 (CTLA4)
US20100267637A1 (en) * 2007-12-13 2010-10-21 Sciclone Pharmaceuticals, Inc. Treatment of melanoma with alpha thymosin peptides in combination with a kinase inhibitor
WO2009079338A1 (en) * 2007-12-14 2009-06-25 Sciclone Pharmaceuticals, Inc. Treatment of melanoma with alpha thymosin peptides in combination with an antineoplastic heat shock apoptosis activator (hsaa)
WO2010001617A1 (en) 2008-07-04 2010-01-07 Ono Pharmaceutical Co., Ltd. Use of an efficacy marker for optimizing therapeutic efficacy of an anti-human pd-1 antibody on cancers
CA2736816C (en) 2008-09-12 2018-05-22 Isis Innovation Limited Pd-1 specific antibodies and uses thereof
HUE030807T2 (en) 2008-09-26 2017-05-29 Dana Farber Cancer Inst Inc Human anti-PD-1, anti-PD-L1 and anti-PD-L2 antibodies and their applications
EP3192811A1 (en) 2009-02-09 2017-07-19 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
CN101591397A (zh) * 2009-07-01 2009-12-02 石继红 长效胸腺素α1的重组表达及其用途
EP2675272A4 (en) * 2011-02-09 2015-03-11 Sciclone Pharmaceuticals Inc THYMOSINE ALPHA PEPTIDE FOR THE PREVENTION, TREATMENT AND TREATMENT OF INFECTIONS
DK2699264T3 (en) 2011-04-20 2018-06-25 Medimmune Llc ANTIBODIES AND OTHER MOLECULES BINDING B7-H1 AND PD-1
JP5790345B2 (ja) * 2011-09-07 2015-10-07 株式会社リコー 画像処理装置、画像処理方法、プログラムおよび画像処理システム
ES2871910T3 (es) * 2012-08-30 2021-11-02 Amgen Inc Un método para tratar el melanoma usando un virus de herpes simple y un inhibidor de puntos de control inmunitario
WO2016064969A1 (en) 2014-10-21 2016-04-28 Sciclone Pharmaceuticals, Inc. Treatment of cancer with immune stimulators

Also Published As

Publication number Publication date
RU2017117194A (ru) 2018-11-22
ZA201702111B (en) 2019-06-26
SG11201702558VA (en) 2017-05-30
RU2020142556A (ru) 2021-02-12
RU2017117194A3 (es) 2019-04-09
EP3209321A1 (en) 2017-08-30
KR20170070091A (ko) 2017-06-21
US20200289618A1 (en) 2020-09-17
AU2015335979B2 (en) 2021-05-20
US9724395B2 (en) 2017-08-08
JP2021088557A (ja) 2021-06-10
CN113855806A (zh) 2021-12-31
TW201615209A (zh) 2016-05-01
US20160106812A1 (en) 2016-04-21
TWI749433B (zh) 2021-12-11
IL251761B (en) 2020-09-30
WO2016064969A1 (en) 2016-04-28
MX386613B (es) 2025-03-19
CA2962451C (en) 2023-01-17
RU2740288C2 (ru) 2021-01-12
AU2015335979A1 (en) 2017-04-20
JP6821560B2 (ja) 2021-01-27
KR102589557B1 (ko) 2023-10-16
TWI683667B (zh) 2020-02-01
JP7175334B2 (ja) 2022-11-18
JP2018501192A (ja) 2018-01-18
US11571465B2 (en) 2023-02-07
EP3209321B1 (en) 2021-06-23
EP3209321A4 (en) 2018-10-31
ES2882080T3 (es) 2021-12-01
US20230285513A1 (en) 2023-09-14
TW202034946A (zh) 2020-10-01
CN107148279B (zh) 2021-09-03
BR112017007817A2 (pt) 2017-12-19
IL251761A0 (en) 2017-06-29
CA2962451A1 (en) 2016-04-28
US20180161399A1 (en) 2018-06-14
EP3943101A1 (en) 2022-01-26
CN107148279A (zh) 2017-09-08

Similar Documents

Publication Publication Date Title
MX2017005134A (es) Tratamiento del cáncer con inmunoestimuladores.
MX2020011104A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
MX394252B (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf
CO2019002371A2 (es) Adenovirus armado con captador biespecífico de linfocitos t (bite)
MX2022007472A (es) Uso de plinabulina en combinacion con inhibidores de punto de control inmunitario.
MX2020012137A (es) Inhibidores de mcl-1.
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
CL2018003588A1 (es) Uso de inhibidores de miostatina y terapias de combinación.
MX2015013948A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
MX2016016744A (es) Inhibidores de ezh2 para tratar linfomas.
UY37581A (es) Compuestos para el tratamiento de la infección por virus de la hepatitis b
BR112017005693A2 (pt) método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica.
BR112017011536A2 (pt) terapias de combinação
CR20150376A (es) Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos
MX2016015363A (es) Terapias de combinacion para el tratamiento de cancer.
BR112018070852A2 (pt) composições de dissulfeto de selênio para uso no tratamento de disfunção das glândulas meibomianas
MX2019009853A (es) Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres.
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
SV2017005418A (es) Inhibidor de cinasa aurora a
CL2018002793A1 (es) Terapia de cáncer con un virus oncolítico combinado con un inhibidor de puntos de control
AR101312A1 (es) Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida